000118221 001__ 118221
000118221 005__ 20240319081023.0
000118221 0247_ $$2doi$$a10.3390/antiox11061086
000118221 0248_ $$2sideral$$a129662
000118221 037__ $$aART-2022-129662
000118221 041__ $$aeng
000118221 100__ $$0(orcid)0000-0003-0349-9997$$aPinilla, Isabel$$uUniversidad de Zaragoza
000118221 245__ $$aInherited retinal dystrophies: role of oxidative stress and inflammation in their physiopathology and therapeutic implications
000118221 260__ $$c2022
000118221 5060_ $$aAccess copy available to the general public$$fUnrestricted
000118221 5203_ $$aInherited retinal dystrophies (IRDs) are a large group of genetically and clinically heteroge-neous diseases characterized by the progressive degeneration of the retina, ultimately leading to loss of visual function. Oxidative stress and inflammation play fundamental roles in the physiopathology of these diseases. Photoreceptor cell death induces an inflammatory state in the retina. The activation of several molecular pathways triggers different cellular responses to injury, including the activation of microglia to eliminate debris and recruit inflammatory cells from circulation. Therapeutical options for IRDs are currently limited, although a small number of patients have been successfully treated by gene therapy. Many other therapeutic strategies are being pursued to mitigate the deleterious effects of IRDs associated with oxidative metabolism and/or inflammation, including inhibiting reactive oxygen species’ accumulation and inflammatory responses, and blocking autophagy. Several compounds are being tested in clinical trials, generating great expectations for their implementation. The present review discusses the main death mechanisms that occur in IRDs and the latest therapies that are under investigation. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
000118221 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B08-17R$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/PI20-00740$$9info:eu-repo/grantAgreement/ES/ISCIII/RETICS-FEDER-RD16-0008-0016$$9info:eu-repo/grantAgreement/ES/MEC/FPU16-04114
000118221 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000118221 590__ $$a7.0$$b2022
000118221 592__ $$a1.084$$b2022
000118221 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b46 / 285 = 0.161$$c2022$$dQ1$$eT1
000118221 593__ $$aBiochemistry$$c2022$$dQ1
000118221 591__ $$aFOOD SCIENCE & TECHNOLOGY$$b13 / 142 = 0.092$$c2022$$dQ1$$eT1
000118221 593__ $$aClinical Biochemistry$$c2022$$dQ1
000118221 591__ $$aCHEMISTRY, MEDICINAL$$b6 / 60 = 0.1$$c2022$$dQ1$$eT1
000118221 593__ $$aFood Science$$c2022$$dQ1
000118221 593__ $$aPhysiology$$c2022$$dQ1
000118221 593__ $$aMolecular Biology$$c2022$$dQ2
000118221 593__ $$aCell Biology$$c2022$$dQ2
000118221 594__ $$a8.8$$b2022
000118221 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000118221 700__ $$aManeu, Victoria
000118221 700__ $$aCampello, Laura
000118221 700__ $$aFernández Sánchez, Laura
000118221 700__ $$aMartínez Gil, Natalia
000118221 700__ $$aKutsyr, Oksana
000118221 700__ $$aSánchez Sáez, Xabier
000118221 700__ $$aSánchez Castillo, Carla
000118221 700__ $$aLax, Pedro
000118221 700__ $$aCuenca, Nicolás
000118221 7102_ $$11013$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Oftalmología
000118221 773__ $$g11, 6 (2022), 1086 [55 pp.]$$pAntioxidants$$tAntioxidants$$x2076-3921
000118221 8564_ $$s814468$$uhttps://zaguan.unizar.es/record/118221/files/texto_completo.pdf$$yVersión publicada
000118221 8564_ $$s2649880$$uhttps://zaguan.unizar.es/record/118221/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000118221 909CO $$ooai:zaguan.unizar.es:118221$$particulos$$pdriver
000118221 951__ $$a2024-03-18-16:27:04
000118221 980__ $$aARTICLE